FDA, DEA May Act More In Unison After Prodding From Congress, GAO
Executive Summary
House passes bill that would speed up DEA’s scheduling of newly approved controlled substances; FDA official says drug shortages are unrelated to DEA quotas.
You may also be interested in...
Drug Shortage Analysis Puts FDA At Loggerheads With GAO
GAO says ongoing drug shortages are increasing, but FDA says they are flattening; contrasting definitions of “shortage” produce the disparate results.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.